832114-06-4

Basic information

• Product Name: (4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE
• Synonyms: (4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE;4-(4-METHYLPIPERAZINE-1-CARBONYL)PHENYLBORONIC ACID, PINACOL ESTER;4-(4-Methyl-1-piperazinylcarbonyl)benzeneboronic acid pinacol ester, 97%;(4-Methyl-piperazine-1-yl)-[4-(4;2-dioxaborolan-2-yl)-phenyl]-Methanone;5-tetraMethyl-1;1-Methyl-4-{[4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbonyl}piperazine;(4-Methylpiperazin-1-yl)(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)Methanone
• CAS NO: 832114-06-4
• Molecular Formula: C18H27BN2O3
• Molecular Weight: 330.23
• EINECS: 200-528-9
• Product Categories: Aryl Boronate Esters;Boronate Esters;Boronic Acids and Derivatives;Chemical Synthesis;Organometallic Reagents
• Mol File: 832114-06-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 110-113°C
• Boiling Point: 463.3°C at 760 mmHg
• Flash Point: 234°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 9.21E-09mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 6.71±0.10(Predicted)
• CAS DataBase Reference: (4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE(832114-06-4)
• EPA Substance Registry System: (4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE(832114-06-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 832114-06-4(Hazardous Substances Data)

Usage

General Description

The chemical compound "(4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE" is a complex organic molecule that contains a piperazine group and a boron containing phenyl ring. It has a molecular formula of C21H30BNO2N2 and a molecular weight of 357.29 g/mol. (4-METHYL-PIPERAZINE-1-YL)-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL]-METHANONE is used in pharmaceutical research and drug development due to its potential therapeutic properties. It may have application in the treatment of various diseases and disorders, although further research is necessary to fully understand its potential uses and effects.

InChI:InChI=1/C18H27BN2O3/c1-17(2)18(3,4)24-19(23-17)15-8-6-14(7-9-15)16(22)21-12-10-20(5)11-13-21/h6-9H,10-13H2,1-5H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 349395-87-5 (4-bromophenyl)-(4-methylpiperazin-1-yl)methanone 
• 73183-34-3 bis(pinacol)diborane 
• 586-75-4 4-chlorobenzoyl chloride 
• 586-76-5 4-Bromobenzoic acid 

Downstream Products

• 1464150-36-4 (4-(3-(4-hydroxyphenyl)imidazo[l,2-a]pyrazin-6-yl)phenyl)(4-methylpiperazin-l-yl)methanone 

Relevant articles and documents

Derivatives with uracil-benzothiazole structure, preparation method of derivatives, and application of anti-HCV drugs

According to the invention, a new series of uracil-benzothiazole NS5B RdRp inhibitors are designed and synthesized; the compounds have the structure shown in a general formula (1), wherein the uracil-benzothiazole NS5B RdRp inhibitor provided by the inven

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, e